Viridian Therapeutics, Inc. (VRDN)

17.00 -0.53 (-3.02%) USD  |  NASDAQ  |  May 07, 16:00
17.10 +0.10 (+0.59%) Pre-Market: 08:27
More

Viridian Therapeutics Research and Development Expense (Annual) : 338.47M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for VRDN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Amgen, Inc. 6.974B
Boston Scientific Corp. 2.052B
Marker Therapeutics, Inc. 11.80M
Plus Therapeutics, Inc. 8.379M
Nutriband, Inc. 1.891M